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Furthermore, we demonstrate that the missense-mutant 
desmin inflicts changes of the subcellular localization and 
turnover of desmin itself and of direct desmin-binding part-
ners. Our findings unveil a novel principle of pathogenesis, 
in which not the presence of protein aggregates, but disrup-
tion of the extrasarcomeric intermediate filament network 
leads to increased mechanical vulnerability of muscle fib-
ers. These structural defects elicited at the myofiber level 
finally impact the entire organ and subsequently cause 
myopathy and cardiomyopathy.
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Abstract Mutations of the human desmin gene on chro-
mosome 2q35 cause autosomal dominant, autosomal reces-
sive and sporadic forms of protein aggregation myopathies 
and cardiomyopathies. We generated R349P desmin knock-
in mice, which harbor the ortholog of the most frequently 
occurring human desmin missense mutation R350P. These 
mice develop age-dependent desmin-positive protein aggre-
gation pathology, skeletal muscle weakness, dilated cardio-
myopathy, as well as cardiac arrhythmias and conduction 
defects. For the first time, we report the expression level 
and subcellular distribution of mutant versus wild-type 
desmin in our mouse model as well as in skeletal muscle 
specimens derived from human R350P desminopathies. 
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Introduction
Desmin is a member of the intermediate filament (IF) pro-
tein gene family, which comprises 70 members and rep-
resents one of the most highly mutated groups of related 
genes in the human genome [21]. Mutations in human IF 
genes have been linked to at least 94 different disease enti-
ties ranging from skin, hair and nail diseases (keratins, 
lamin A/C), eye disorders (keratins, vimentin, phakinin), 
degenerative disorders of the central and peripheral nervous 
system (glial fibrillary acidic protein, neurofilament pro-
teins, peripherin, lamin A/C), premature aging syndromes 
(lamin A/C), lipodystrophy and metabolic syndromes 
(lamin A/C) to skeletal muscle and cardiac diseases (lamin 
A/C, desmin) [34, 41].
Desmin, the most abundant IF protein in skeletal, car-
diac and smooth muscle cells, is the central component 
of the filamentous extrasarcomeric cytoskeleton, which 
links neighboring myofibrils and connects the myofibrillar 
apparatus with the subsarcolemmal cytoskeleton, myonu-
clei, mitochondria, intercalated discs as well as myotendi-
nous and neuromuscular junctions. This three-dimensional 
framework has essential roles in the alignment and anchor-
age of myofibrils, the resistance of muscle cells against 
mechanical stress, the positioning of cell organelles, and 
signaling events [12]. Desmin exhibits a tripartite struc-
ture with a central α-helical rod domain flanked by non-
α-helical amino-terminal head and carboxy-terminal 
tail domains. The rod domain consists of two continuous 
α-helical segments, which are interconnected by a linker 
(L12) polypeptide sequence. Rod domain coil 1 itself com-
prises two α-helical subdomains, which are tied by a sec-
ond linker (L1) sequence [9, 12, 20, 33] (Fig. S1a).
Human desmin, a 470-amino acid protein with a calcu-
lated molecular mass of 53.5 kDa, is encoded by a single 
copy gene (DES) on chromosome 2q35 [27]. Since the first 
description of myopathy- and cardiomyopathy-causing 
DES mutations [16], over 70 mutations have been reported, 
which spread over the entire DES gene, thus affecting the 
structure and function of the head, rod, and tail domains of 
the protein [12]. A significant clustering of DES mutations 
is observed in exon 6, which encodes the C-terminal half 
of the coil 2 domain within the desmin rod (Fig. S1a). The 
vast majority of genetically proven desminopathies follows 
an autosomal dominant trait of inheritance. In addition, rare 
autosomal recessive cases with an earlier and more severe 
disease manifestation as well as an increasing number of 
sporadic desminopathies have been described [12].
Human desminopathies are characterized by a marked 
phenotypic variability with either pure skeletal muscle or 
cardiac pathology or a combination of both. The progres-
sive skeletal muscle disease may manifest as distal, limb 
girdle, scapuloperoneal, or generalized myopathy pheno-
types. Cardiac disease manifestation comprises true car-
diomyopathy, conduction defects, and arrhythmias [12]. 
Desminopathies are morphologically characterized by 
sarcoplasmic and subsarcolemmal desmin-positive pro-
tein aggregates and degenerative changes of the myofibril-
lar apparatus. They are the classical protagonists of the 
expanding group of myofibrillar myopathies (MFMs), a 
numerically significant subgroup of hereditary and sporadic 
protein aggregate myopathies with marked clinical and 
genetic heterogeneity due to mutations of the desmin, αB-
crystallin, BAG-3, FHL1, filamin-C, myotilin, plectin, and 
ZASP genes [37].
We previously described the clinical, myopathologi-
cal, and molecular consequences of the human heterozy-
gous R350P DES mutation in several German families [3, 
46]. This missense mutation residing in exon 6 (Fig. S1a) 
is the most frequently encountered gene defect causing 
desminopathies and leads to a single amino acid exchange 
from arginine to proline at position 350, which represents 
a b position in the heptad pattern characteristic for coiled 
coil forming α-helices. Actually, arginine 350 is part of 
the sole undeca-repeat in the center of coil 2 that harbors 
the “stutter”. Here, both helices of the coiled coil exhibit 
a short-unwound region as demonstrated for the corre-
sponding, nearly identical domain of the vimentin dimer 
[39]. In transfection studies the R350P desmin mutant was 
not capable to form a de novo desmin network in IF-free 
cells, disrupted the pre-existing, endogenous vimentin IF 
network in 3T3 cells, and led to the formation of cytoplas-
mic protein aggregates. Moreover, R350P desmin showed a 
highly abnormal pattern in in vitro desmin filament assem-
bly experiments. R350P desmin aborted the normal fila-
ment assembly already at an early stage and led to patho-
logical protein aggregation. Already the presence of 25 % 
of the mutant desmin effectively aborted the normal polym-
erization process of desmin IFs [3].
Studies on the molecular pathogenesis of human desmi-
nopathies are generally hampered by the fact that muscle 
biopsies from affected patients reflect only late stages of 
the disease process, are only available in small amounts, 
and biopsy material from pre-clinical, early and inter-
mediate disease stages is not accessible [12]. Thus, we 
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generated a R349P desmin knock-in mouse model for 
human desminopathies. Since murine desmin, compared 
to human desmin, lacks a serine at position 82 (Fig. S1a), 
murine R349 is the ortholog of human R350 (both pro-
teins further differ in 11 conservative amino acid changes; 
sequence identity is 97 %). Here, we report the clinical, 
electrophysiological, hemodynamic, radiological, myo-
pathological, biomechanical, and molecular findings in het-
erozygous (HET) and homozygous (HOM) R349P desmin 
knock-in mice as compared to wild-type (WT) littermates. 
Our knock-in mouse strain represents the first physiological 
animal model for autosomal dominant and recessive human 
desminopathies, as the expression of the mutant desmin is 
controlled by the endogenous gene regulation sites.
Materials and methods
For complete and detailed information on the animal 
model, all methods, materials, and devices used in this 
study please refer to the Supplemental Methods. Data 
analyses and statistical evaluations were performed using 
Excel 2010 (Microsoft); the Kruskal–Wallis one-way 
analysis of variance, Mann–Whitney U (Wilcoxon rank-
sum), Fisher’s exact, Chi-squared, and 1-way ANOVA 
with Bonferroni subgroup statistical tests were done using 
the Excel add-in “Real Statistics Resource Pack” ver-
sion 3.1.2 by Charles Zaiontz available at http://www.
real-statistics.com/; the Lord test was manually calculated 
according to [22]. When the Mann–Whitney U test was 
used for post hoc analyses, it was used without further cor-
rection of the level of significance, as only two samples 
were compared to a single control. The number of inde-
pendent experiments, mean values, standard errors, type of 
statistical test, and significance levels are indicated in the 
“Results” section or Figure legends. Final assembly and 
preparation of all figures for publication was done using 
Corel Draw Graphics Suite X4.
Generation and genotyping of R349P desmin knock-in 
mice
The R349P desmin knock-in mouse model B6J.129Sv- 
Destm1(R349P)Cscl&Rfsr was generated according to our speci-
fications (CSC, RS) by genOway, Lyon, France. Routine 
genotyping was performed by PCR. In addition, mice were 
genotyped at random by Southern blotting, and the pres-
ence of the R349P desmin point mutation was verified 
by sequencing. Mice were housed in isolated ventilated 
cages (IVC) under specific and opportunistic pathogen-
free (SOPF) conditions at a standard environment with free 
access to water and food. Health monitoring was done as 
recommended by the Federation of European Laboratory 
Animal Science Associations (FELASA). Mice were han-
dled in accordance with the German Animal Welfare Act 
(Tierschutzgesetz) as well as the German Regulation for 
the protection of animals used for experimental purposes 
or other scientific purposes (Tierschutz-Versuchstierver-
ordnung), and the investigations were approved by the 
responsible governmental animal care and use office (North 
Rhine-Westphalia State Agency for Nature, Environment 
and Consumer Protection (LANUV), Recklinghausen, Ger-
many; reference number 8.87-50.10.31.09.045).
Investigation of striated muscle function
Grip strength was measured using a BIO-GS3+ grip 
strength meter (Bioseb, Vitrolles, France). For the wire 
hanging test mice were placed on a wire cage lid, which 
was slowly turned upside down. Electrostimulation of 
explanted soleus muscles for determination of twitch and 
tetanic force recordings were performed as described pre-
viously (supplemental experimental procedures in [1]). 
For passive-stretch experiments, small fiber bundles of five 
single fibers were dissected from soleus muscles and trans-
ferred to an automated force transducer system with step-
wise length increases according to [44].
Cardiac phenotyping
Functional cardiac magnetic resonance imaging (CMR) of 
the left ventricle was performed using a 4-element cardiac 
phased-array coil on a dedicated 11.7 T small animal MRI 
system (BioSpec 117/16, Bruker, Ettlingen, Germany), 
applying a self-gated imaging technique (IntraGate, Bruker, 
Ettlingen, Germany [19]). For echocardiography, a Sonos 
5500 (Philips, Eindhoven, The Netherlands) with a S12 
transducer (12 MHz) was used, and the performing person 
was blinded during procedure as previously described [36]. 
Pressure volume loop recordings were made in closed-
chest, spontaneously breathing mice using a 1.2-French 
catheter (Model FT111B, SciSense Inc., London, ON, Can-
ada) inserted into the left ventricle of the mice to simul-
taneously measure pressure and volumes as previously 
described [5, 36].
Surface, long-term, and intracardiac electrophysiological 
investigations
A surface 6-lead electrocardiogram was continuously mon-
itored and analyzed under stable conditions [2]. For long-
term electrocardiography analysis in conscious animals, 
telemetry devices (Modell EA-F20; DataSciences Interna-
tional, St. Paul, MN, USA) were implanted according to 
[14], and the leads were directed ventrally and fixed to the 
pectoral muscle in an Eindhoven II position. Recordings 
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were performed 10 days after recovery from surgical 
instrumentation. All baseline recordings were performed 
in conscious animals for 24 h in a constant environment. 
At the end of the baseline recording a physical stress test, 
i.e., 10 min swimming exercise, was performed under 
continuation of electrocardiogram recording as described 
before [23]. In vivo transvenous electrophysiological 
investigations were performed using a 2-French octapolar 
mouse electrophysiological catheter (eight 0.5 mm circular 
electrodes, electrode-pair spacing 0.5 mm; Ciber Mouse, 
NuMed Inc., NY, USA) positioned in the right cardiac 
cavities on atrial and ventricular level. Intracardiac elec-
trograms and transvenous atrial and ventricular stimula-
tion maneuvers were registered and recorded as previously 
described [35].
Human skeletal muscle biopsy material
Tissue samples of skeletal muscle derived from a diagnos-
tic muscle biopsy of a patient from a previously reported 
family with a heterozygous R350P desmin mutation [46] 
were obtained from the Friedrich-Baur-Institute, Munich, 
Germany.
Preparation of striated muscle sections, 
immunohistochemistry, immunofluorescence stains, 
and ultrastructural analysis
Skeletal and cardiac muscle specimens were collected, 
immediately frozen in liquid nitrogen-cooled isopentane, 
sectioned, further prepared, and used for standard histol-
ogy and immunofluorescence stains; images were acquired 
using a LSM780 fluorescence laser scanning microscope 
(Carl Zeiss GmbH, Oberkochen, Germany) and a Leica 
TCS SP5/AOBS/tandem scanning system (Leica Microsys-
tems GmbH, Wetzlar, Germany). For quantitation of myo-
cardial fibrosis, sections of paraffin embedded myocardial 
whole heart samples were stained with Sirius red, and 
fibrosis was defined as the percent area of extracellular 
Sirius red staining. Murine cardiomyocytes were isolated 
according to [42], and immunofluorescence analyses were 
performed after attachment of the cells to laminin-coated 
microscope slides. For transmission electron microscopy, 
soleus muscle specimens were prepared following stand-
ard protocols and examined with a LEO906E transmis-
sion electron microscope (Carl Zeiss GmbH, Oberkochen, 
Germany).
Real-time polymerase chain reactions
Analyses of the mRNA expression levels of brain natriu-
retic peptide (BNP), desmin, and desmin-binding partners 
were done using cDNA derived from striated muscle of the 
R349P desmin knock-in mice. Quantitative real-time PCR 
was performed on an ABI PRISM 7000 (Applied Biosys-
tems, Foster City, USA), an Opticon II instrument (MJ 
Research Inc., St. Bruno, Quebec, Canada), and a CFX 
Connect Real-Time PCR Detection System (Bio-Rad Lab-
oratories, Hercules, CA, USA). GAPDH, AIP1, and HPRT 
genes were used as reference genes, appropriate quality 
controls were performed, and data were analyzed using the 
delta–delta-Cq-Method (ΔΔCq). Expression ratios are dis-
played as fold change in relation to the wild-type control 
samples.
Determination of wild-type and R350P/R349P mutant 
desmin mRNA levels
Complementary DNA derived from striated muscle of 
a R350P desminopathy patient and HET R349P desmin 
knock-in mice was used for PCR, and PCR products 
were either directly subjected to restriction digestion 
or first cloned into pGEM-Teasy (Promega Corpora-
tion, Madison, WI, USA) for transformation into E. coli, 
growth of colonies, use for colony PCR, and then sub-
jected to restriction digestion. As the desmin point muta-
tion destroys an endogenous AciI restriction site in human 
and inserts a novel AvaI restriction site in mouse, the 
amounts of wild-type and mutant desmin mRNA can be 
determined.
Desmin antibodies
Two desmin antibodies were newly generated for the pur-
pose of this study. Rabbits were immunized with hepta-
peptides surrounding amino acid residue 350/349 of 
desmin (wild-type peptide C-MRQMREL, mutant pep-
tide C-MRQMPEL; PSL Peptide Specialty Laboratories 
GmbH, Heidelberg, Germany) and affinity purified. Wild-
type R350/R349 desmin specifically was detected by rab-
bit pAb HD2 (1:1,000 in TBS-T for Western blotting), 
and R350P/R349P mutant desmin by rabbit pAb HD350P 
(1:1,000 in TBS-T for Western blotting, 1:200 in PBS for 
immunofluorescence).
Both wild-type and R350P/R349P mutant desmin were 
detected by three commercially available “pan-desmin” 
antibodies (D1033, Sigma-Aldrich (St. Louis, MO, USA), 
mouse mAb, 1:400 in TBS-T for Western blotting; D33, 
Dako (Glostrup, Denmark), mouse mAb, 1:400 in PBS-T 
for Western blotting, 1:50 or 1:100 in PBS for immunofluo-
rescence; 10570, Progen Biotechnik GmbH (Heidelberg, 
Germany), rabbit pAb, 1:100 in PBS for immunofluores-
cence). See the Supplemental Methods for information on 
other antibodies.
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Gel electrophoresis techniques, in vitro dephosphorylation, 
and mass spectrometry
For reproducible immunoblotting extraction of proteins 
from striated muscle tissue was done according to [10]. For 
protein quantitation, a fluorometric dye (ProStain, Active 
Motif, Carlsbad, CA, USA) was used. 2D-SDS-PAGE was 
performed according to [11], mass spectrometry accord-
ing to [13]. In vitro dephosphorylation assays were done as 
described in [48].
Expression of recombinant desmin in E. coli and insect 
cells
Recombinant human wild-type and R350P mutant desmin 
cloned into pTriEx1.1-Neo, which contains a bacterial T7, 
a mammalian CMV as well as an insect cells baculovirus 
p10 promoter, were expressed in E. Coli BL21(DE3)pLysS 
cells [40] and Sf9 insect cells.
Cycloheximide assay
For effective blockade of protein synthesis mice received 
daily s. c. injections at their neck of 60 mg/kg cyclohex-
imide, typically 180 µl of a 10 mg/ml solution in PBS, 
for 4 days (d1–d4); first injections (d0) were with PBS 
only. Control mice daily received only PBS. Mice were 
killed by cervical dislocation, and tissues were dis-
sected and snap-frozen in liquid nitrogen for further 
analyses. The administered dose of cycloheximide was 
derived from [15, 28, 29, 32, 38, 43] and ChemIDplus at 
http://chem.sis.nlm.nih.gov/chemidplus/ (LD50 mouse 
s.c.: 160 mg/kg).
Results
R349P desmin knock-in mice: a model for human R350P 
desminopathies
Heterozygous R349P desmin knock-in mice were gen-
erated using a gene targeting strategy, which replaced 
the triplet “AGG” (human “CGG”) encoding arginine 
by “CCC” (human “CCG”) encoding proline in exon 6. 
After homologous recombination and removal of the neo-
mycin selection cassette by Cre recombinase, the origi-
nal gene structure is preserved and only a single LoxP 
site remains in intron 6. The correct targeting event was 
confirmed by Southern blotting, PCR genotyping, and 
sequencing of genomic DNA (Fig. S1b–e). Crossbreeding 
of HET mice resulted in the generation of HOM R349P 
mice. Though homozygous R350P desmin patients have 
not been described yet, our HOM mice depict essential 
aspects of rare autosomal recessive desminopathies due 
to missense, small in-frame deletion, and compound het-
erozygous mutations [12]. Both HET and HOM desmin 
R349P knock-in mice are viable and fertile, showed no 
overt behavioral abnormalities, and the assessment of body 
weight, heart weight, heart-to-body weight, heart weight-
to-tibia length ratios, and serum creatine kinase levels 
showed no statistically significant differences between the 
genotypes (data not shown).
Expression and decay of wild-type versus point-mutated 
desmin
A direct comparison of the human and murine desmin-
related pathology is a central aspect of the present study. 
To determine the expression levels of wild-type and 
R350P mutant desmin mRNAs in humans, we performed 
RT-PCRs from a diagnostic skeletal muscle biopsy of a 
German patient with a heterozygous R350P desmin muta-
tion (Fig. 1a). This analysis showed that 55 % of total 
desmin mRNA is derived from the mutant allele (Fig. 1b). 
Analogous experiments using skeletal and cardiac mus-
cle tissue from HET R349P desmin knock-in mice 
revealed 43 and 55 % mutant desmin mRNA, respectively 
(Fig. 1c–f).
In contrast to our initial immunoblotting which dem-
onstrated a single desmin band at 53 kDa [3], our cur-
rent analysis using high-resolution SDS-PAGE in con-
junction with desmin immunoblotting revealed that the 
human R350P and the murine R349P mutant desmin pro-
teins migrate slower than wild-type desmin (Fig. 1g). In 
the desminopathy patient, approximately 20 % of total 
desmin protein is the mutant variant. In HET mice, the 
relative quantity of mutant desmin was within a range 
of 20–50 % in both skeletal and cardiac muscle tissue. 
Similar amounts of mutant desmin were also observed in 
Coomassie brilliant blue stained 2D-gels of skeletal and 
cardiac muscle tissue lysates (data not shown). In HOM 
mice, only mutant desmin with markedly reduced sig-
nal intensity was detected by immunoblotting. Here, the 
amount of mutant desmin was in a range from hardly 
detectable up to 30 % as compared to the signal intensity 
wild-type desmin.
To further address the aberrant migration pattern of 
mutant desmin with respect to putative differential post-
translational modifications, we expressed recombinant 
human desmin in E. coli, Sf9 insect and HEK293 mam-
malian cells. Mutant desmin expressed in these different 
systems, which are, respectively, limited, partially, and 
fully capable of mammalian post-translational modifica-
tions, displayed identical migration patterns in SDS-PAGE 
and urea-PAGE (Fig. S2a). Moreover, no decrease in the 
higher apparent molecular mass of mutant desmin could be 
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observed in in vitro dephosphorylation assays using pro-
tein extracts from human as well as murine skeletal muscle 
tissue (Fig. S2b). Thus, the aberrant migration pattern of 
mutant desmin must be due to structural changes induced 
by the replacement of the arginine by a proline side chain 
in the desmin rod domain coil 2.
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Since the commercially available desmin antibody detects 
both the mutant and the wild-type desmin, we generated rab-
bit polyclonal antibodies that specifically detect either the 
mutant or the wild-type desmin (Fig. 1h). Using these anti-
bodies, we investigated the wild-type and R349P mutant 
desmin decay in skeletal muscle tissue of mice, in which 
protein synthesis was completely inhibited by cyclohex-
imide treatment (Fig. 2a–c). These studies demonstrated that 
the decay of desmin in HET and HOM mice was acceler-
ated when compared to WT animals. Moreover, not only 
the mutant, but also the wild-type desmin content showed a 
faster decay in HET mice, and mutant desmin disappeared 
more rapidly in HOM than in HET mice.
Structural pathology of skeletal and cardiac muscle 
in R349P desmin knock-in mice
Our myopathological analysis revealed clear evidence 
of skeletal muscle myopathy in HOM mice, in which we 
observed an age-related increase in the extent of degen-
erative muscle changes consisting of increased endomysial 
connective tissue, rounding of muscle fibers, pathologi-
cal fiber sizes variations, centralization of myonuclei, and 
degenerating muscle fibers in soleus muscle tissue. These 
age-related changes were accompanied by a correspond-
ing aggravation of mitochondrial abnormalities comprising 
multiple muscle fibers with focal changes of cytochrome C 
oxidase (COX) (Fig. 3a, b) and succinate dehydrogenase 
(SDH) (data not shown) enzyme activities. Similar myo-
pathic alterations were detected in the diaphragm of HOM 
mice, while no such changes could be detected in gastroc-
nemius and quadriceps femoris muscles (data not shown). 
At the ultrastructural level, soleus muscle from HOM mice 
showed massive subsarcolemmal protein aggregate pathol-
ogy, autophagic vacuoles, Z-band streaming, and lysis 
of myofibrils (Fig. 3c). In line with the highly abnormal 
COX staining, electron microscopy further revealed focal 
accumulation or depletion of mitochondria as well as giant 
mitochondria. The analysis of skeletal muscle tissue from 
3- and 16-month-old HET R349P mice showed no overt 
myopathic alterations indicating that the observed expres-
sion level of R349P mutant desmin is not sufficient to 
induce progressive skeletal muscle damage in these mice. 
In contrast, the morphological analysis of cardiac muscle 
tissue revealed pathological alterations consistent with a 
cardiomyopathy in both genotypes. Here, H&E and Sirius 
red stains revealed increased connective tissue in HET and, 
more prominent, in HOM mice (Fig. S3).
Desmin protein aggregation pathology in skeletal 
and cardiac muscle
Using the newly generated mutant desmin-specific anti-
body, we were able to reveal the subcellular distribution 
of the mutant desmin in human and murine muscle tissue 
[Fig. 4 (for details); Fig S4 (for overview)]. Analysis of 
cross-sections from a diagnostic muscle biopsy specimen 
of a R350P desminopathy patient revealed that the R350P-
specific antibody only labeled a subset of fibers in which 
the mutant desmin was primarily localized in the subsar-
colemmal region and, to a lesser extent, in small sarco-
plasmic aggregates (Fig. S4b). At higher magnification, a 
mixture of fibers with gross alterations of the sarcoplasmic 
desmin network and protein aggregates, and fibers with 
virtually no R350P desmin expression could be visualized 
(Fig. 4a). Corresponding desmin immunostains were per-
formed in soleus muscle from 3- and 16-month-old R349P 
Fig. 1  Expression levels of wild-type and mutant desmin mRNA 
and protein in human and murine striated muscle tissue. a To address 
the expression level of wild-type and R350P mutant desmin mRNA 
in skeletal muscle tissue from a desminopathy patient, we performed 
RT-PCRs in conjunction with AciI restriction digestion. Since the 
presence of the R350P missense mutation destroys an endogenous 
AciI restriction site, the 310 bp RT-PCR product, a mixture derived 
from wild-type and mutant mRNA, is incompletely digested into the 
179 and 131 bp fragments in the desminopathy patient. b To quan-
titate the levels of wild-type and mutant desmin mRNA, the 310 bp 
mixed product was cloned into the pGEM-Teasy vector, transformed 
into E. coli, and single colonies were used for a colony PCR. AciI 
restriction digestions of these PCR products resulted in either 310 bp 
or the 179 and 131 bp fragments, and were used to determine the 
relative amounts of wild-type and mutant desmin mRNA in the het-
erozygous R350P desminopathy patient. c–f Analogous experiments 
were performed in skeletal and cardiac muscle tissue derived from 
R349P desmin knock-in mice. Here, the presence of the R349P mis-
sense mutation creates a novel AvaI restriction site. Note, that the rela-
tive amounts of wild-type and mutant desmin mRNA in skeletal and 
cardiac muscle from HET mice are within a similar range as the one 
observed in human R350P desminopathy skeletal muscle. a, c For 
illustration, lines from the same agarose gel were digitally re-arranged. 
g The presence of the R350P and R349P mutation in man and mouse, 
respectively, alters the migration pattern of the desmin molecule in 
SDS-PAGE. Since the mutant displayed a slower migration pattern, 
desmin immunoblotting allows quantitation of wild-type and mutant 
desmin on the protein level. Upper panel, two distinct desmin bands 
are visible in skeletal muscle tissue from a desminopathy patient. The 
amount of mutant desmin (upper band) is significantly reduced as 
compared to the amount of wild-type desmin. Middle and lower pan-
els, corresponding immunoblots using skeletal and cardiac muscle tis-
sue from WT, HET, and HOM mice. In WT and HOM animals, only 
single bands of desmin were detected, whereas HET mice displayed 
the double-band pattern as observed in the human situation. Note the 
markedly reduced levels of R349P mutant desmin protein in HOM 
mice. Protein concentrations were determined using the “ProStain” 
fluorometric dye (Active Motif) and equal amounts of proteins from 
WT, HET, and HOM tissue lysates were loaded. h Immunoblotting of 
wild-type versus R349P mutant desmin in cardiac muscle tissue from 
knock-in mice using a set of three different desmin-specific antibod-
ies. Uppermost lane detection of wild-type and mutant desmin using 
a commercially available mouse monoclonal desmin antibody. Sec-
ond panel we generated a rabbit polyclonal antibody that specifically 
detects the wild-type (R349) desmin in WT and HET mice, but not the 
mutant. Third panel exclusive detection of the mutant desmin (P349) 
in HET and HOM mice by a second newly generated rabbit polyclonal 
antibody. Lowermost panel GAPDH for loading control
◂
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desmin knock-in mice (Fig. S4c, d). Using the pan-desmin 
antibody, muscle tissue from young HOM animals already 
displayed a highly abnormal staining pattern with fib-
ers containing multiple subsarcolemmal and sarcoplasmic 
desmin-positive protein aggregates as well as multiple fib-
ers with virtually no sarcoplasmic desmin staining. In con-
trast, pan-desmin stains in HET R349P mice showed no 
obvious changes in comparison to age-matched wild-type 
controls. Using the mutant-specific desmin antibody, how-
ever, the presence and an age-dependent increase of R349P 
desmin protein aggregation pathology could be visualized 
in soleus muscle of HET and HOM mice (Fig. S4c, d). Fur-
thermore, comparison of the protein aggregation pathology 
in different muscle groups revealed that the level of mutant 
desmin was much more abundant in diseased soleus mus-
cle than in gastrocnemius and quadriceps femoris mus-
cles, which showed no myopathic alterations. Analysis 
of longitudinal sections of gastrocnemius muscle derived 
from HET animals demonstrated that the mutant desmin is 
not incorporated into the cross-striated wild-type desmin 
cytoskeleton, but segregated into desmin-positive protein 
aggregates (Fig. 4b; Fig. S4e).
The analysis of cardiac tissue derived from HOM R349P 
mice showed a highly abnormal desmin-staining pattern in 
which the mutant desmin is enriched at the level of inter-
calated discs as well as in small dotted protein aggregates 
in the sarcoplasm of individual cardiomyocytes (Fig. S5a). 
It is noteworthy that these small protein aggregates often 
displayed a seemingly regular dotted pattern in homozy-
gous tissue and isolated cardiomyocytes. Though the nor-
mal cross-striated desmin-staining pattern, which is seen in 
HET and WT animals, was completely abolished, the latter 
finding might indicate that the R349P mutant desmin can 
still associate to the level of the Z-discs, but itself is inca-
pable of forming a filamentous three-dimensional desmin 
cytoskeleton (Fig. S5b).
Mutant desmin changes the subcellular localization 
and turnover of its direct, extrasarcomeric binding partners
The extrasarcomeric cytoskeleton in mature striated muscle 
cells is primarily composed of desmin, the type IV IF pro-
teins synemin and syncoilin, as well as the multifunctional 
cytolinker plectin. Synemin, syncoilin, and plectin are well-
established direct desmin-binding partners and exert essen-
tial roles in the anchorage of pre-formed desmin filaments 
to the sarcolemma, the periphery of myofibrillar Z-discs, 
and neuromuscular and myotendinous junctions [12]. In 
skeletal muscle specimens from desminopathy patients, 
synemin (Fig. S6), syncoilin (Fig. 7 in [12]), and plectin 
(Fig. 2 in [3]) co-localized with desmin in subsarcolemmal 
and sarcoplasmic protein aggregates. In our mouse model, 
we were able to demonstrate that the expression of R349P 
mutant desmin severely affected the subcellular distribu-
tion of desmin-binding partners of the extrasarcomeric 
cytoskeleton (Fig. 5). In HOM mice, synemin and plectin 
were found to be enriched in the subsarcolemmal region 
and in protein aggregates, while their sarcoplasmic stain-
ing signal was markedly reduced. In HET animals, a less 
strikingly reduced sarcoplasmic staining of synemin and 
plectin as well as an enhanced subsarcolemmal staining of 
plectin was visible. Vimentin immunofluorescence imaging 
Fig. 2  Enhanced desmin turnover in R349P desmin knock-in mice. 
a–c Wild-type and R349P mutant desmin protein levels in skeletal 
muscle tissue of mice, in which protein synthesis was completely 
inhibited by cycloheximide treatment over a time span of 4 days. 
The amounts of wild-type and R349P mutant desmin were deter-
mined by immunoblotting using the pan-desmin, R349 wild-type-, 
and P349 mutant-specific antibodies. Graphs were generated from 
densitometry analyses of single, representative experiments, and the 
obtained desmin intensity values were normalized to both the total 
protein content as determined by Coomassie Brilliant Blue stained 
SDS-PAGE gels and the desmin densitometry values at day 0. In a 
and b the densitometry values of HET and HOM mice were addition-
ally normalized to the ones of WT animals. a Determination of the 
total desmin amount using the pan-desmin antibody revealed that the 
decline of desmin in HET and HOM mice is accelerated as compared 
to WT animals. The second, dotted WT curve illustrates the amount 
of desmin in WT mice only normalized to day 0. b Determination of 
the amount of wild-type desmin (R349) showed that it also declined 
faster in HET mice. c Determination of the amount of R349P mutant 
desmin in HET and HOM animals. Here, the mutant desmin in HOM 
mice declined more rapidly than in HET mice, which express both 
wild-type and mutant desmin
305Acta Neuropathol (2015) 129:297–315 
1 3
showed no evidence of vimentin expression in the diseased 
skeletal muscle fibers (data not shown).
The observed alterations in the subcellular distribution 
of desmin and its direct binding partners are associated 
with changes in the respective mRNA and protein expres-
sion levels. QRT-PCR analyses demonstrated a marked 
up-regulation of desmin mRNA in HOM R349P knock-in 
mice (Fig. 6a). Taken into account that the desmin protein 
level is dramatically reduced in this genotype, these results 
indicate a highly increased protein turnover of the mutant 
desmin. Moreover, HOM R349P desmin knock-in mice 
showed markedly increased synemin and syncoilin mRNA 
levels (Fig. 6b, c). In HET animals, the total desmin and 
syncoilin mRNA levels were found to be higher than in 
WT, but lower than in HOM animals. On the protein level, 
the expression of syncoilin was markedly reduced in both 
R349P desmin genotypes, whereas the synemin levels were 
seemingly unchanged (Fig. 6d–f).
From pathology of the extrasarcomeric cytoskeleton 
to muscle weakness and increased mechanical vulnerability 
of skeletal muscle fibers
To address clinically relevant skeletal muscle weakness, 
we performed a multi-level investigation. In a first step, 
animals were monitored in vivo by 4-paw grip strength 
measurements and wire hanging tests. Young animals up 
to an age of 12 months showed no significant differences 
between the genotypes (data not shown). The analysis of 
1.5-year-old WT, HET, and HOM animals revealed a sta-
tistically significant reduction in the 4-paw grip strength 
in HOM mice as compared to WT mice (Fig. 7a). These 
animals also showed a highly pathological performance in 
the wire hanging test (WT, n = 5, 124.4 s vs. HOM, n = 8, 
58.5 s; p < 0.005, Lord test). To further substantiate the 
observed changes in single muscle groups, soleus muscles 
from some of the above animals were explanted and sub-
jected to twitch and tetanic force recordings. Homozygous 
muscles developed significantly reduced forces in both 
tests as compared to WT (Fig. 7b–d). Corresponding analy-
ses were performed using explanted extensor digitorum 
longus muscles. Here, no significant changes in the force 
development were detected (data not shown).
To address the passive biomechanical properties of skel-
etal muscle fibers, chemically skinned small fiber bundles 
from soleus muscles derived from other, 4.5-month-old 
mice were step-wise stretched using an automated force 
transducer system. Five fiber bundles from HET and mark-
edly more pronounced from HOM mice exhibited higher 
biomechanical stiffness, i.e., increased restoration force at 
identical extensions, than those from WT mice, indicating 
that the expression of mutant desmin reduced fiber elas-
ticity (Fig. 7e). In addition, the fiber bundles from HOM 
mice, and to a lesser extent from HET mice, were prone to 
passive-stretch-induced fiber ruptures (Fig. 7f).
From mutant desmin to dilated cardiomyopathy, cardiac 
conduction defects, and arrhythmias
Cardiac pathology comprising cardiomyopathy, conduc-
tion defects and arrhythmias significantly contributes to 
the increased mortality rate and reduced life expectancy 
in patients with autosomal dominant and recessive desmi-
nopathies [12]. Similarly, cardiac assessment in both HET 
and HOM R349P desmin knock-in mice revealed a com-
bined picture of cardiomyopathy, conduction defects and 
arrhythmias. Functional cardiac magnetic resonance imag-
ing (CMR) showed the typical signs of dilated cardio-
myopathy with significantly reduced stroke volumes and 
ejection fractions in combination with increased end-sys-
tolic and end-diastolic volumes in 2-year-old HOM mice 
(Fig. S7). In vivo assessment of cardiac hemodynamics by 
pressure volume loop recordings with determination of dP/
dtmax values revealed decreased myocardial contractility 
in 1-year-old HOM animals (Fig. S8a), whereas impaired 
contractility in HET animals could not be detected before 
the age of 2 years (Fig. S8b). Thus, in keeping with our 
morphological analysis, also aged HET knock-in animals 
developed a significant cardiomyopathy. The diagnosis of 
cardiomyopathy in these aged HET mice was further sub-
stantiated by a 1.9-fold increase in BNP mRNA expression 
levels (WT, n = 5, HET, n = 8, p < 0.05, Lord test).
Extensive electrophysiological investigations in young, 
6-month-old R349P desmin knock-in mice demonstrated 
a broad spectrum of cardiac abnormalities already at this 
age. Long-term telemetric baseline electrocardiography 
recordings showed sinus rhythm in all animals. Atrial and 
ventricular extrasystoles could be registered in both mutant 
genotypes, whereas spontaneous atrial fibrillation (AF) or 
ventricular tachycardias (VT) were not detected (Fig. S9a, 
b). During stress tests, i.e., swimming exercise, the num-
ber of premature ventricular contractions significantly 
increased in mutant mice (Fig. S9c; WT, n = 3, 4.0 ± 6.9 
events/h, HET, n = 3, 65.3 ± 51.4 events/h, HOM, n = 3, 
21.0 ± 12.7 events/h; p < 0.0001, Chi-squared test). In 
addition, HET and HOM mice showed higher grade atrio-
ventricular and sino-atrial blocks (Fig. S9d, e) under con-
ditions of stress during the telemetry ECG recordings 
(WT, 0.5 ± 0.7 events/h, HET, 3.3 ± 0.6 events/h, HOM, 
15.0 ± 4.2 events/h; p < 0.0012, Chi-squared test).
The surface electrocardiography recordings demonstrated 
no differences in cardiac conduction times, i.e., P-, PQ-, 
QRS-, and QTc-intervals. In a next step, 3-month-old animals 
underwent catheterization for intracardiac electrography for 
assessment of supra-Hisian AV nodal conductance (AH inter-
val) and infra-Hisian conduction times (HV interval). This 
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analysis demonstrated normal AH intervals, but significantly 
prolonged HV intervals in HET and HOM mice (Fig. S8c, d). 
Furthermore, we noted the occurrence of 2nd and 3rd degree 
AV blocks in HET and HOM mice, which never occurred in 
WT animals (Fig. S10a). Transvenous atrial and ventricular 
stimulation maneuvers further revealed increased numbers of 
episodes with AF and VTs in both genotypes (Fig. S8e, f). In 
contrast to WT animals, in which only short, self-terminating 
episodes of AF could be induced, both HET and HOM mice 
displayed long-lasting (>1 min) AF-episodes (Fig. S10b). 
Ventricular stimulations also led to a significant increase in 
the number of VT episodes in mutant mice (Fig. S10c).
Discussion
The majority of IF diseases are caused by heterozygous 
missense mutations leading to pathogenic, single amino 
acid exchanges. Since almost all available antibodies do 
not allow a distinction between IF protein species that dif-
fer only by a single amino acid, the expression level, sub-
cellular distribution, and turnover of wild-type and mutant 
IF protein species cannot be directly assessed in diseased 
human tissues or animal models. The creation of a R349P 
desmin knock-in mouse model expressing untagged mutant 
desmin in conjunction with the generation of a R349P 
mutant-specific antibody allowed us to analyze these cen-
tral issues in relation to the clinical, hemodynamic, mor-
phological, and biomechanical aspects of desminopathies.
From in vitro to in vivo: how much mutant desmin is 
needed to cause protein aggregation pathology in striated 
muscle?
Our previous IF assembly assays demonstrated that pres-
ence of already 25 % of the human R350P desmin mutant 
in mixtures with wild-type desmin effectively ablated the 
normal polymerization process of desmin IFs [3]. These in 
vitro findings imply that the ratio of mutant versus wild-
type desmin is a critical issue. We therefore studied the 
expression of both desmin mRNA and protein in human 
and murine striated muscle tissues. Our analysis of human 
R350P skeletal muscle revealed that 55 % of total desmin 
mRNA was derived from the mutant allele, whereas the 
values were 43 and 55 %, respectively, in skeletal and 
cardiac muscle tissue derived from HET R349P desmin 
knock-in mice. Though the relative amounts of mutant and 
wild-type desmin mRNA were seemingly balanced, our 
quantitative RT-PCR analysis revealed that the total lev-
els of desmin mRNA were constantly increased in striated 
muscle tissue of our HET R349P desmin knock-in mice. In 
contrast, immunoblot analysis showed only 20 % of mutant 
desmin in total protein extracts derived from human R350P 
skeletal muscle, and a range of 20–50 % in striated muscle 
from HET R349P mice. Thus, our HET mice closely mir-
ror the expression levels of mutant and wild-type desmin in 
heterozygous human R350P mutation carriers.
With regard to the pathophysiology of autosomal domi-
nant desminopathies, our expression data in man and 
mice may provide a novel understanding of the results 
in two previously reported transgenic mouse models for 
desminopathies. In one model, the low expression rate 
of only 10 % of a HA-tagged L345P mutant desmin may 
explain the very mild clinical skeletal and cardiac mus-
cle phenotypes as well as the lack of desmin aggrega-
tion pathology [24]. In contrast, a second model with the 
p.Arg173_Glu179del desmin transgene showed a threefold 
overexpression of the mutant protein. Though this model 
developed a progressive protein aggregate cardiomyopa-
thy [47], such high expression levels of a mutant desmin 
do not occur in heterozygous human mutation carriers [12]. 
However, beyond the critical expression level of the mutant 
desmin, specific properties of the individual desmin muta-
tions and their subcellular distributions are likely to con-
tribute to the observed phenotypes.
In comparison to the desmin protein levels in WT and 
HET animals, our HOM R349P knock-in mice showed 
markedly reduced amounts of desmin. The virtual lack of 
desmin expression in the only two reported human auto-
somal recessive desminopathies, however, seems to be 
related to a different disease mechanism. In one case with 
a 22-base pair deletion in exon 6 causing a premature stop 
codon, dramatically reduced levels of both mutant desmin 
mRNA and protein were reported. Muscle biopsies from 
these patients showed a myopathic pattern, but no protein 
aggregates on the ultrastructural level [8]. In contrast to 
our HOM mouse model, the mutant desmin mRNA in the 
homozygous mutations carriers was dramatically reduced 
to <0.5 % possibly due to nonsense-mediated mRNA 
Fig. 3  Age-related skeletal muscle pathology and ultrastructural 
analysis of soleus muscle in R349P desmin knock-in mice. a Hema-
toxylin and eosin (H&E) and cytochrome C oxidase (COX) stains of 
transverse cryosections from 3-month-old animals. While HET mice 
showed no overt pathology, HOM mice displayed moderate degen-
erative muscle changes with increased connective tissue, pathological 
variation of fiber diameters, and centralization of myonuclei. In addi-
tion, COX stains revealed multiple fibers with areas of diminished 
enzyme staining. b Marked, age-related progression of dystrophic 
alterations in 16-month-old HOM mice. In addition to a further 
increase in connective tissue, degenerating fibers became appar-
ent. Compared to 3-month-old animals, the aged mice also showed 
a marked accentuation of the mitochondrial pathology as revealed 
by COX staining. Note the presence of multiple fibers with strongly 
diminished sarcoplasmic and/or increased subsarcolemmal enrich-
ment of enzyme staining. c In addition to massive subsarcolemmal 
protein aggregate pathology and autophagic vacuoles, various degen-
erating myofibrils, and marked Z-band streaming as additional signs 
of myofibril degeneration are depicted
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Fig. 4  Subcellular distribution 
of wild-type and mutant desmin 
in human and murine skeletal 
muscle tissue. a Analysis of 
human R350P desminopathy 
skeletal muscle tissue using the 
R350P desmin mutation-specific 
antibody. High magnification of 
a single muscle fiber containing 
massive subsarcolemmal and 
multiple sarcoplasmic protein 
aggregates. Neighboring fibers 
showed less alterations (arrow) 
or almost no expression of the 
mutant desmin (asterisk). b 
Pan-desmin and R349P desmin 
stains in longitudinal sections of 
murine gastrocnemius muscle 
derived from HET mice. Note, 
that the regular cross-striated 
desmin pattern (pan-desmin) is 
mainly preserved. In contrast, 
the R350P desmin is only 
present in pathological protein 
aggregates (yellow in the 
merged image)
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decay. In another patient with compound heterozygote trun-
cation mutations (p.Thr76fsX21, p.Glu108X) a complete 
ablation of desmin protein was described [19]. Though no 
mRNA levels were reported in this study, the ablation of 
desmin protein also may be attributed to a nonsense-medi-
ated mRNA decay.
The complete lack of wild-type desmin and the low 
amounts of mutant R349P desmin in our HOM R349P 
desmin knock-in mice further highlight and validate essen-
tial aspects of our previously reported transfection and in 
vitro assembly studies using human R350P desmin [3]. In 
line with these studies, our analysis of HOM R349P desmin 
knock-in animals clearly demonstrated that the desmin 
mutant itself is incapable of forming a desmin network and 
leads to the formation of desmin-positive protein aggregates 
in striated muscle cells. Thus, the lack of wild-type desmin 
and the intrinsic inability of the mutant desmin to form a 
functional desmin IF network are the primary key events in 
the molecular sequence that lead to progressive skeletal and 
cardiac muscle damage in HOM R349P desmin knock-in 
Fig. 5  Altered subcellular distribution of direct desmin-binding part-
ners in skeletal muscle tissue of R349P desmin knock-in mice. Syn-
emin, syncoilin, and plectin are well-established direct desmin inter-
action partners, which together form the extrasarcomeric cytoskeleton 
in striated muscle cells. All three proteins displayed altered subcel-
lular distributions with accumulation in the subsarcolemmal region 
and diminished sarcoplasmic staining of muscle fibers in HOM mice. 
Though to a lesser extent, these changes were also visible in HET 
mice
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mice. However, as several desmin mutants have been 
reported which are capable of forming IF structures in vitro 
or in transfected cells [4], these mutants are likely to exert 
their pathogenic potential via other molecular mechanisms.
Mutant versus wild-type desmin: increased protein 
turnover and segregation into aggregates
The desmin mRNA and protein expression data derived 
from our mice are indicative of an increased desmin turno-
ver rate. To address this issue in more detail, we treated 
our mice with cycloheximide, which completely blocks 
protein synthesis. Immunoblot analysis of the desmin pro-
tein levels in WT, HET, and HOM mice demonstrated that 
the R349P mutant desmin disappeared much faster than 
the wild-type protein. This finding provides an explana-
tion for the markedly reduced desmin protein levels in our 
HOM mice. Moreover, the presence of mutant desmin also 
induced an accelerated decay of wild-type desmin in HET 
mice.
The generation of a mutant-specific desmin anti-
body further enabled us for the first time to visualize the 
Fig. 6  Aberrant intermediate filament expression in R349P desmin 
knock-in mice. a–c Quantitative real-time RT-PCR analyses of 
desmin, synemin, and syncoilin mRNA expression in soleus mus-
cle tissue derived from WT, HET, and HOM mice. Though desmin 
protein levels were markedly reduced in HOM mice, a significant 
up-regulation of desmin mRNA is seen in this genotype indicating a 
highly increased protein turnover. In HET mice, the desmin mRNA 
levels were found to be higher than in WT animals, but lower than in 
HOM mice. An analogous pattern was detected for syncoilin, whereas 
in case of synemin mRNA, only HOM mice showed an up-regulation. 
Mean values and standard errors were obtained by fourfold repeated 
measurements in nine (desmin, syncoilin) or four (synemin) 3-month-
old animals per genotype. Columns represent relative values with 
wild-type expression scaled to 1. p values were calculated using the 
Kruskal–Wallis one-way analysis of variance; post hoc analyses were 
performed using the Mann–Whitney U test. d Synemin and syncoilin 
immunoblotting of lysates from soleus muscle. While the synemin 
protein levels were slightly increased in HET and unchanged HOM 
mice, the expression of syncoilin was significantly reduced in both 
R349P desmin genotypes. GAPDH was used as loading control. e, f 
Densitometry analyses of synemin and syncoilin immunoblots. Col-
umn charts were generated from analyses of 16 sets of synemin and 9 
sets of syncoilin WT, HET, and HOM bands and show relative values 
with wild-type expression scaled to 1. p values were calculated using 
the Kruskal–Wallis one-way analysis of variance; post hoc analyses 
were performed using the Mann–Whitney U test
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subcellular distribution of mutant desmin in human and 
murine striated muscle tissue. In man and mice, the mutant 
desmin was predominantly detected in protein aggregates 
in the subsarcolemmal region, and, to a lesser extent, in the 
sarcoplasm of skeletal muscle fibers. In cardiomyocytes of 
HET and HOM mice, the R349P desmin was primarily 
found at the level of intercalated discs. Importantly, the 
analysis of skeletal and cardiac muscle tissue from HET 
animals revealed that mutant desmin was not incorporated 
into the cross-striated, wild-type desmin cytoskeleton, but 
was segregated into subsarcolemmal and sarcoplasmic 
protein aggregates.
Fig. 7  From skeletal muscle weakness to increased mechanical 
vulnerability of isolated muscle fibers. a Analyses of 19-month-old 
R349P desmin knock-in mice revealed a significant reduction of 
the 4-paw grip strength in HOM mice (n = 8), whereas HET mice 
(n = 2) displayed values matching those of WT animals (n = 7). 
Columns represent mean values from five measurements per animal, 
error bars indicate standard errors of the mean, b–d soleus mus-
cles from some of these animals (WT, n = 6, HET, n = 2, HOM, 
n = 7) were explanted and subjected to twitch (b) and tetanic force 
(c) recordings. Columns represent averaged peak values from ten 
measurements per muscle, error bars indicate standard errors of the 
mean. d Typical myograph curves of tetanic force development dur-
ing electrostimulation. a–d since we were only able to include two 
HET animals they were excluded from statistical evaluations; sta-
tistical significance of WT vs. HOM was calculated using the Lord 
test. e Representative example recordings of passive force during 
step-wise increase in stretch of 5-fiber bundles from soleus muscles 
of 4.5-month-old mice. During each step-increase in stretch, resto-
ration force quickly jumps to a maximum, followed by exponential 
force decay due to elastic relaxation of elastic elements in the bun-
dles. Larger force responses indicate higher biomechanical stiffness, 
i.e., reduced elasticity. Note the increased stiffness in HET and, more 
markedly, in HOM animals. f The expression of R349P desmin leads 
to an increased mechanical vulnerability of the isolated muscle fiber 
bundles. While all five wild-type fibers and three out of five heterozy-
gote fibers remained intact up to a resting length of 150 %, four out 
of five fibers derived from HOM animals were ruptured
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From mutant desmin via pathology of the extrasarcomeric 
cytoskeleton to altered biomechanical properties of muscle 
fibers
We demonstrated that the expression of mutant desmin not 
only leads to an increased turnover of desmin protein species, 
but also increases the turnover or changes the subcellular 
distribution of synemin, syncoilin, and plectin, all of which 
are direct desmin-binding partners and key components of 
the extrasarcomeric cytoskeleton. Thus, mutant desmin ulti-
mately damages the structural and functional organization 
of the three-dimensional extrasarcomeric IF cytoskeleton on 
multiple levels, however, with distinct differences between 
individuals carrying one or two mutated alleles. In heterozy-
gous human and murine muscle tissue the IF pathology is 
characterized by focal disruptions of the IF network in a sub-
set of fibers. Given the multi-nuclear nature of skeletal mus-
cle fibers, these focal disruptions of the IF cytoskeleton in 
heterozygous man and mice may preferentially be triggered 
in areas with higher levels of mutant desmin protein.
In HOM R349P knock-in mice and autosomal recessive 
human desminopathies the pathology is clearly different. 
Here, no wild-type desmin is present and the disruption of the 
IF cytoskeleton is no longer focal but omnipresent in every 
striated muscle cell. The latter observation is clearly reminis-
cent of the findings in desmin knock-out mice, in which the 
lack of a desmin network leads to a progressive myopathy and 
cardiomyopathy [18, 25, 31]. However, in desmin knock-out 
mice the complete ablation of desmin neither altered the sub-
cellular localization of plectin [7] nor led to protein aggrega-
tion pathology [25, 26, 30]. Moreover, desmin knock-out mice 
displayed calcifications in the cardiac tissue that were not 
present in our R349P desmin knock-in model [25, 30]. The 
comparison of the desmin knock-out and our HOM R349P 
knock-in mice highlights the importance of the structural and 
functional integrity of the extrasarcomeric IF cytoskeleton, but 
also implies that the mutant desmin exerts different biological 
effects than the pure lack of wild-type desmin.
In striated muscle, the desmin filament system has been 
attributed to play a cell-protective role against mechani-
cal stress by dissipating mechanical energy during muscle 
contraction [12]. To address the question if the observed 
extrasarcomeric IF pathology alters the passive biome-
chanical properties of skeletal muscle fibers in our R349P 
desmin knock-in mice, we performed analyses on chemi-
cally skinned small fiber bundles from soleus muscles, 
which were step-wise stretched. Here, we were able to 
demonstrate a higher restoration force reflecting a higher 
stiffness and an increased susceptibility to passive-stretch-
induced ruptures of muscle fibers from both genotypes. 
These findings basically mirror the results of our biome-
chanical analysis of primary myoblasts derived from a 
patient with a heterozygous R350P desmin mutation, which 
displayed increased cell stiffness and a higher rate of cell 
death and substrate detachment [6]. Our data demonstrates 
for the first time that the presence of mutant desmin protein 
changes the functional properties of the extrasarcomeric 
cytoskeleton and subsequently alters the biomechanical 
properties of striated muscle fibers. The observed increase 
of stiffness is likely to inflict changes in the adaptability of 
striated muscle cells to mechanosensing and mechanotrans-
duction, and may thus essentially contribute to the progres-
sive skeletal and cardiac muscle damage in desminopathies.
Desmin protein aggregate pathology: a matter of age 
and muscle groups
Our mutant-specific desmin antibody proved to be invaluable 
for the detection of an age- and muscle group-dependent pro-
tein aggregation pathology in HET R349P desmin knock-in 
mice. We observed a dramatic increase in number and size of 
desmin-positive protein aggregates in aged mice in compari-
son to young animals. Moreover, we demonstrated that the 
protein aggregation pathology in soleus muscle was much 
more abundant than in gastrocnemius or quadriceps femoris 
muscles. The former muscle is mainly composed of slow-
twitch type 1 fibers with a high content of mitochondria, 
whereas the latter two are mainly composed of fast-twitch 
type 2 fibers. Taken into account that marked dystrophic 
changes and severe concomitant mitochondrial abnormali-
ties were only present in soleus muscles of HOM mice, these 
findings strongly imply that expression of mutant desmin is 
more harmful for slow-twitch muscle fibers.
Pathogenic significance of desmin protein aggregates 
in striated muscles
Desmin-positive protein aggregates are the morphological 
hallmark of desminopathies and all other MFMs. How-
ever, it is an open debate if, and to what extent, these pro-
tein aggregates contribute to the development of progres-
sive muscle damage and weakness. In the present study, we 
demonstrate that marked desmin-positive protein aggrega-
tion can be present without concomitant myopathological 
alterations or skeletal muscle weakness. Thus, our data 
strongly imply that total or focal disruption of the extrasar-
comeric IF cytoskeleton rather than the presence of desmin 
protein aggregates per se is the key factor that triggers the 
progressive muscle fiber damage in autosomal dominant 
and recessive desminopathies.
Desminopathies in man and mice: similarities 
and differences
In contrast to both previously published transgenic desmi-
nopathy mouse models [24, 47], our knock-in approach 
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has the striking advantage that the expression of the mutant 
desmin gene remains under control of the endogenous gene 
regulation sites. Thus, our HET animals express the R349P 
mutant desmin in the physiological range that we detected 
in heterozygous human mutation carriers. As in humans, 
our HOM animals with the omnipresent extrasarcomeric 
cytoskeletal pathology display an earlier and more severe 
disease manifestation as HET mice, in which the disruption 
of three-dimensional IF network was more focal in nature. 
Desmin-positive protein aggregates, the morphological hall-
mark of desminopathies and all other forms of MFMs, were 
present in both HET and HOM mice, but clear evidence of 
progressive skeletal muscle weakness and morphological 
signs of myopathic alterations was only present in the latter. 
In human heterozygous mutation carriers, the R350P desmin 
mutation is associated with marked clinical variability rang-
ing from severely to only mildly affected patients with dif-
ferent clinical presentations of skeletal muscle weakness [3, 
46]. Though we cannot rule out that the observed level of 
mutant R349P desmin protein in our HET knock-in mice is 
principally not sufficient to induce progressive skeletal mus-
cle damage, we presume that the limited physical activity of 
our sedentary laboratory mice basically prevents the devel-
opment of muscle weakness and damage.
In contrast, the cardiological workup demonstrated all 
three desmin-related cardiac disease manifestations in HET 
and HOM mice, i.e., true cardiomyopathy, conduction 
defects, and arrhythmias. As in humans, our mice displayed 
high incidence of AV conduction blocks, which was accom-
panied by a marked prolongation of the infra-Hisian AV 
time indicating reduced electrical impulse propagation in the 
Purkinje fiber network. Since desmin is the most abundant 
protein in these fibers [45], the expression of mutant desmin 
may significantly disturb the cellular function of the cardiac 
conduction system. This might explain the high susceptibil-
ity of desminopathy patients to life-threatening conduction 
defects. As in R350P desmin mutation carriers sudden cardiac 
death is frequently occurring, partially independent from the 
onset of severe heart failure symptoms [46], such potentially 
asymptomatic patients have to be surveyed comprehensively 
and early implantation of a pacemaker or implantable cardio-
verter–defibrillator (ICD) may be indicated. Furthermore, the 
high incidence of VTs appearing in the R349P knock-in mice 
may be attributed to the presence of dilated cardiomyopathy 
and the interstitial myocardial fibrosis [17].
From R349P desmin knock-in mice towards therapeutic 
implications
To date, no specific or ameliorating therapy is available for 
desminopathies and all other forms of MFMs. Even the 
basic clinical question if physical activity would be benefi-
cial or harmful for affected patients cannot be answered on 
the basis of the available clinical and scientific literature. Our 
observation that the structural and functional disturbances of 
the extrasarcomeric cytoskeleton led to an increased suscep-
tibility of muscle fibers to mechanical strain implicates that 
in patients with desminopathies physical activity beyond a 
certain threshold or duration might aggravate the skeletal or 
cardiac disease progression. Our insights into the molecular 
pathogenesis also put a focus on pharmacological compounds 
that inhibit the increased IF protein turnover we observed in 
our R349P desmin knock-in mice. If effective, they might 
ameliorate the decay of the extrasarcomeric cytoskeleton in 
some autosomal dominant desminopathies, facilitate segrega-
tion of mutant desmin into harmless protein aggregates, and 
thus slow down the disease progression. Here, it is tempting 
to speculate that proteasome inhibitors, which already found 
their way into clinical practice, could be promising therapeu-
tic drugs for some desmin mutation carriers protecting the 
extrasarcomeric cytoskeleton from degradation.
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